Vor Biopharma Inc.

VOR | NASDAQ

Price Alert Chart Builder DCF Calculator

$23.23

+$1.34 (+6.12%)

Sep 22, 2026, 11:07 AM ET · Market open

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

+6.12%

(1D)

Rating

Updated: Aug 19, 2026

23.4

Fundamentals Weak

Market Sentiment Bullish

Moat None

Full Analysis

Key Statistics

Market Data

Market Cap $1.26B

1D Range

21.72 23.41

52W Range

6.50 49.95

Valuation (TTM)

PE -0.04

PB -5.92

EV/EBITDA 1.12

Valuation (NTM)

Forward PE N/A

Forward PEG 0.00

Price Target $29

Cash Flow

FCF Yield -11.9%

SBC Adj. FCF Yield -14.9%

SBC Impact -25.0%

Margins

Gross Margin 0.0%

Operating Margin 0.0%

FCF Margin N/A

Growth (CAGR)

Revenue 3Y | 5Y N/A | N/A

Dil EPS 3Y | 5Y -92.6% | -67.6%

FCF 3Y | 5Y -15.1% | -11.6%

Returns

ROA 130.5%

ROE -91.6%

ROIC -32.2%

Financial Health

Net Cash

$466.13M

Current Ratio 19.15

Interest Coverage 0.00

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

Vor Biopharma, Inc. is a clinical-stage biotechnology firm dedicated to developing innovative engineered hematopoietic stem cell (eHSC) therapies for individuals battling cancer. Its lead product cand...

Sector Healthcare

Industry Biotechnology

Employees 76

IPO Date Feb 4, 2021

Website www.vorbio.com

Fiscal Year January - December

Full Company Profile

Latest News

13 days ago · seekingalpha.com

Vor Biopharma Inc. (VOR) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

21 days ago · globenewswire.com

Vor Bio To Participate in Upcoming September Conferences

BOSTON, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that management will participate in the following investor conferences: Wells Fargo 21st Annual Healthcare Conference Forum: Fireside Chat and 1x1 Meetings Date: Tuesday, September 8th Presentation Time: 8:00AM ET Citi's 2026 Biopharma Back to School Conference Forum: Fireside Chat and 1x1 Meetings Date: Wednesday, September 9th Presentation Time: 11:20AM ET Morgan Stanley 24th Annual Global Healthcare Conference Forum: 1x1 Meetings Date: Monday, September 14th Baird's 2026 Global Healthcare Conference Forum: Presentation and 1x1 Meetings Date: Tuesday, September 15th Presentation Time: 9:05AM ET Stifel's 2026 Virtual Immunology and Inflammation Forum Forum: Presentation and 1x1 Meetings Date: Wednesday, September 23rd Presentation Time: 11:30AM ET A live webcast of the presentation may be accessed on the Investors section of the Vor website at ir.vorbio.com.

2 months ago · globenewswire.com

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, on August 1, 2026, the Compensation Committee of the Board of Directors granted stock options to purchase an aggregate of 32,550 shares of Vor Bio's common stock and restricted stock units ("RSUs") representing the right to receive an aggregate of 6,900 shares of Vor Bio's common stock to 5 newly hired employees.

Analyst Summary

# of Analysts

Consensus

Buy

Price Target

$29

Upside

+24.84%

Buy (3)

Hold (1)

Sell (0)

Analyst Details ➞